Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Xiao Nan Hong"'
Autor:
Xiang‐Nan Jiang, Fang Yu, Tian Xue, Qing‐Xin Xia, Qian‐Ming Bai, Bao‐Hua Yu, Ruo‐Hong Shui, Xiao‐Yan Zhou, Xiong‐Zeng Zhu, Jun‐Ning Cao, Xiao‐Nan Hong, Xiao‐Qiu Li
Publikováno v:
Cancer Medicine, Vol 12, Iss 9, Pp 10684-10693 (2023)
Abstract Purpose Large B‐cell lymphoma with IRF4 rearrangement (LBCL, IRF4+) has been recently recognized as a specific entity that is frequently associated with young age and favorable prognosis. However, whether the good outcome of the disease is
Externí odkaz:
https://doaj.org/article/e24e1a0217d54169a97fc36fc6fe77eb
Autor:
William Townsend, Wolfgang Hiddemann, Christian Buske, Guillaume Cartron, David Cunningham, Martin J.S. Dyer, John G. Gribben, Elizabeth H. Phillips, Martin Dreyling, John F. Seymour, Andrew Grigg, Judith Trotman, Tong-Yu Lin, Xiao-Nan Hong, Dirk Kingbiel, Tina G. Nielsen, Andrea Knapp, Michael Herold, Robert Marcus
Publikováno v:
HemaSphere, Vol 7, Iss 7, p e919 (2023)
The phase III GALLIUM trial assessed the safety and efficacy of obinutuzumab-based versus rituximab-based immunochemotherapy in patients with previously untreated follicular lymphoma (FL) or marginal zone lymphoma (MZL). At the primary analysis, the
Externí odkaz:
https://doaj.org/article/54ee041689654f5486a8b741a193c36c
Autor:
Yuan-Kai Shi, Xiao-Nan Hong, Jian-Liang Yang, Wei Xu, Hui-Qiang Huang, Xiu-Bin Xiao, Jun Zhu, Dao-Bin Zhou, Xiao-Hong Han, Jian-Qiu Wu, Ming-Zhi Zhang, Jie Jin, Xiao-Yan Ke, Wei Li, De-Pei Wu, Shen-Miao Yang, Xin Du, Yong-Qian Jia, Ai-Chun Liu, Dai-Hong Liu, Zhi-Xiang Shen, Lian-Sheng Zhang, Leonard James, Edward Hellriegel, Peng Lyu
Publikováno v:
Chinese Medical Journal, Vol 134, Iss 11, Pp 1299-1309 (2021)
Abstract. Background:. Bendamustine was approved in China on May 26th, 2019 by the National Medical Product Administration for the treatment of indolent B-cell non-Hodgkin lymphoma (NHL). The current study was the registration trial and the first rep
Externí odkaz:
https://doaj.org/article/2e136575615e46fc9bd3c8c49fd5d2b5
Autor:
Xiang‐Nan Jiang, Fang Yu, Tian Xue, Qing‐Xin Xia, Qian‐Ming Bai, Bao‐Hua Yu, Ruo‐Hong Shui, Xiao‐Yan Zhou, Xiong‐Zeng Zhu, Jun‐Ning Cao, Xiao‐Nan Hong, Xiao‐Qiu Li
Publikováno v:
Cancer Medicine. 12:10684-10693
Autor:
Wan-Hui Yan, Xiang-Nan Jiang, Wei-Ge Wang, Yi-Feng Sun, Yi-Xin Wo, Zheng-Zhi Luo, Qing-Hua Xu, Xiao-Yan Zhou, Jun-Ning Cao, Xiao-Nan Hong, Xiao-Qiu Li
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
The well-established cell-of-origin (COO) algorithm categorizes diffuse large B-cell lymphoma (DLBCL) into activated B-cell-like (ABC) and germinal center B-cell-like (GCB) subgroups through gene expression profiling. We aimed to develop and validate
Externí odkaz:
https://doaj.org/article/c87f5fe56ad24a29876ab792c605dde4
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e66411 (2013)
BACKGROUND: Non-Hodgkin's lymphoma (NHL) has been widely reported to be associated with autoimmune and pro-inflammatory response, and genetic polymorphisms of candidate genes involved in autoimmune and pro-inflammatory response may influence the surv
Externí odkaz:
https://doaj.org/article/700ff33aa8d1486b8768a893c9683772
Autor:
Yan Zhang, Meng-Yun Wang, Jing He, Jiu-Cun Wang, Ya-Jun Yang, Li Jin, Zhi-Yu Chen, Xue-Jun Ma, Meng-Hong Sun, Kai-Qin Xia, Xiao-Nan Hong, Qing-Yi Wei, Xiao-Yan Zhou
Publikováno v:
PLoS ONE, Vol 7, Iss 5, p e37846 (2012)
BackgroundNon-Hodgkin's lymphoma (NHL) has been reported to be associated with autoimmune and pro-inflammatory response, and genetic polymorphisms of candidate genes involved in autoimmune and pro-inflammatory response may influence the susceptibilit
Externí odkaz:
https://doaj.org/article/235f3b806e5c45999c2b4cf3194e635b
Autor:
Shiang Jiin Leaw, Ye Guo, Jun Ning Cao, Xiao Ying Zhao, Xiao Nan Hong, Zi Ting Li, Jian Hua Chang
Publikováno v:
Medical Oncology. 28:1559-1564
To analyze the clinical characteristics, results of treatment, and prognostic factors of patients diagnosed as primary ovarian non-Hodgkin's lymphoma (PONHL). Fourteen cases of PONHL treated in Fudan University Cancer Center during a 10-year period w
Publikováno v:
Leukemia & Lymphoma. 49:1778-1783
Rituximab is widely used for CD20+ non-Hodgkin lymphoma (NHL). The use of rituximab has been uncommonly associated with pulmonary toxicity. We report here a single institution experience on the clinical characteristics, diagnosis, treatment and outco
Publikováno v:
Blood. 128:5340-5340
Introduction: The addition of rituximab to chemotherapy has been associated with substantial responses in patients with indolent NHL, but patients usually relapse. Bendamustine hydrochloride (bendamustine; Treanda®) is an alkylating agent approved g